How do you approach medication management in patients with RA when transitioning from csDMARD triple therapy to anti-TNF?  

There is not a one-size-fits-all approach to this question. Drug transitions can be influenced by several factors including individual side effects of medications, patient preference for other reasons, disease co-morbidities, ability to use prednisone as bridge therapy, etc. In general, hydroxychlor...

I largely agree. The quality of alternative options with biologics and Jak inhibitors has made this issue largely moot; people do very well no matter how they are transitioned.